Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Benmelstobart
Anlotinib
Nanfang Hospital, Southern Medical University
P3
BB
(64)
Cetuximab
Colorectal Carcinoma
Shanghai Changzheng Hospital
P3
BB
(64)
Donanemab
Central Nervous System Disorder
Eli Lilly and Company
P3
BB
(64)
Elotuzumab
Plasma Cell Myeloma
Hoffmann-La Roche
P3
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4) (HUMAN-MUS MUSCULUS MONOCLONAL M3 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL M3 .KAPPA.-CHAIN, DIMER
Renal Cell Carcinoma
Merck Sharp & Dohme LLC
P3
BB
(64)
Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 ?1-chain), disulfide with human-Mus musculus monoclonal JMT101 ?-chain, dimer
Colorectal Cancer
Shanghai JMT-Bio Inc.
P3
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION)
Systemic-Onset Juvenile Idiopathic Arthritis
Novartis Pharmaceuticals
P3
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
P3
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Lung Cancer
University of Chicago
P3
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Relapsing-Remitting Multiple Sclerosis
University Hospital, Montpellier
P3
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Myelodysplastic Syndrome
Prelude Therapeutics
P3
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(64)
Ipilimumab
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(64)
Ipilimumab
Sarcomatoid Renal Cell Carcinoma
City of Hope Medical Center
P3
BB
(64)
Ipilimumab
Uveal Melanoma
Inge Marie Svane
P3
BB
(64)
Ivonescimab
Colorectal Cancer
UNICANCER
P3
BB
(64)
Ivonescimab
Small Cell Lung Carcinoma
PrECOG, LLC.
P3
BB
(64)
Ivuxolimab
Cancer
Pfizer
P3
BB
(64)
Ixekizumab
Psoriatic Arthritis
NHS Greater Glasgow and Clyde
P3
BB
(64)
Nivolumab
Differentiated Thyroid Carcinoma
Exelixis
P3
BB
(64)
Nivolumab
Anal Margin Squamous Cell Carcinoma
National Cancer Institute (NCI)
P3
BB
(64)
Nivolumab
Anal Squamous Cell Carcinoma
National Cancer Institute (NCI)
P3
BB
(64)
Nivolumab
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)
P3
BB
(64)
Nivolumab
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(64)
Nivolumab
Nonpapillary Renal Cell Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(64)
Showing 451 to 475 of 6,371 assets
Previous
Page 19 of 255
Next